pioglitazone has been researched along with Encephalopathy, Traumatic in 5 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We then hypothesize that optimal pioglitazone dosing will lead to ongoing neuroprotection and cognitive benefits that are dependent on pioglitazone-mitoNEET signalling pathways." | 1.62 | Clinically relevant mitochondrial-targeted therapy improves chronic outcomes after traumatic brain injury. ( Berkowitz, BA; Burden, S; Cloud, AL; Geldenhuys, WJ; Gooch, JL; Harris, NG; Hubbard, WB; Powell, DK; Spry, ML; Sullivan, PG; Vekaria, HJ, 2021) |
| "Pioglitazone treated TBI rats performed significantly better in the RAM test than untreated TBI rats, and similarly to control animals." | 1.51 | Pioglitazone improves working memory performance when administered in chronic TBI. ( Anwar, FN; Correll, EA; Lowery, AC; McCullumsmith, RE; McGuire, JL; Ngwenya, LB; Rhame, K, 2019) |
| "Traumatic brain injury is a leading cause of death and disability around the world." | 1.51 | Pioglitazone treatment prior to transplantation improves the efficacy of human mesenchymal stem cells after traumatic brain injury in rats. ( Das, M; Foran, E; Han, JY; Mayilsamy, K; Mohapatra, S; Mohapatra, SS; Tang, X; Willing, AE, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hubbard, WB | 2 |
| Spry, ML | 1 |
| Gooch, JL | 1 |
| Cloud, AL | 1 |
| Vekaria, HJ | 2 |
| Burden, S | 1 |
| Powell, DK | 1 |
| Berkowitz, BA | 1 |
| Geldenhuys, WJ | 2 |
| Harris, NG | 1 |
| Sullivan, PG | 2 |
| Zamanian, MY | 1 |
| Taheri, N | 1 |
| Opulencia, MJC | 1 |
| Bokov, DO | 1 |
| Abdullaev, SY | 1 |
| Gholamrezapour, M | 1 |
| Heidari, M | 1 |
| Bazmandegan, G | 1 |
| McGuire, JL | 1 |
| Correll, EA | 1 |
| Lowery, AC | 1 |
| Rhame, K | 1 |
| Anwar, FN | 1 |
| McCullumsmith, RE | 1 |
| Ngwenya, LB | 1 |
| Das, M | 1 |
| Mayilsamy, K | 1 |
| Tang, X | 1 |
| Han, JY | 1 |
| Foran, E | 1 |
| Willing, AE | 1 |
| Mohapatra, SS | 1 |
| Mohapatra, S | 1 |
| Yonutas, HM | 1 |
| Pandya, JD | 1 |
1 review available for pioglitazone and Encephalopathy, Traumatic
| Article | Year |
|---|---|
Neuroprotective and Anti-inflammatory Effects of Pioglitazone on Traumatic Brain Injury.
Topics: Animals; Anti-Inflammatory Agents; Brain Injuries, Traumatic; Disease Models, Animal; Humans; Microg | 2022 |
4 other studies available for pioglitazone and Encephalopathy, Traumatic
| Article | Year |
|---|---|
Clinically relevant mitochondrial-targeted therapy improves chronic outcomes after traumatic brain injury.
Topics: Animals; Brain Injuries, Traumatic; Iron-Binding Proteins; Membrane Proteins; Mice; Mice, Inbred C57 | 2021 |
Pioglitazone improves working memory performance when administered in chronic TBI.
Topics: Animals; Brain; Brain Injuries, Traumatic; Chronic Disease; Male; Maze Learning; Memory, Short-Term; | 2019 |
Pioglitazone treatment prior to transplantation improves the efficacy of human mesenchymal stem cells after traumatic brain injury in rats.
Topics: Administration, Intranasal; Animals; Anti-Inflammatory Agents; Brain Injuries, Traumatic; Brain-Deri | 2019 |
Bioenergetic restoration and neuroprotection after therapeutic targeting of mitoNEET: New mechanism of pioglitazone following traumatic brain injury.
Topics: Animals; Brain Injuries, Traumatic; Disease Models, Animal; Energy Metabolism; Iron-Binding Proteins | 2020 |